Tvardi Therapeutics, Inc. (TVRD)

Market Cap	227.70M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	9.36M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,565
Open	24.82
Previous Close	25.21
Day's Range	24.10 - 25.59
52-Week Range	8.13 - 34.31
Beta	n/a
Analysts	Strong Buy
Price Target	60.67 (+149.41%)
Earnings Date	Aug 21, 2025

About TVRD

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: TVRD
• Website: https://tvarditherapeutics.com

Analyst Forecast

According to 3 analysts, the average rating for TVRD stock is "Strong Buy." The 12-month stock price forecast is $60.67, which is an increase of 149.41% from the latest price.

Price Target

$60.67

(149.41% upside)

Analyst Consensus: Strong Buy